ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.

ABSTRACT:

Background

Most melanoma patients with BRAF^V600E positive tumors respond well to a combination of BRAF kinase and MEK inhibitors. However, some patients are intrinsically resistant while the majority of patients eventually develop drug resistance to the treatment. For patients insufficiently responding to BRAF and MEK inhibitors, there is an ongoing need for new treatment targets. Cellular metabolism is such a promising new target line: mutant BRAF^V600E has been shown to affect the metabolism.

Methods

Time course experiments and a series of western blots were performed in a panel of BRAF^V600E and BRAF^WT/NRAS^mut human melanoma cells, which were incubated with BRAF and MEK1 kinase inhibitors. siRNA approaches were used to

SUBMITTER: Cesi G 

PROVIDER: S-EPMC5465587 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature